Skip to main content

Advertisement

Table 1 Pharmacological properties of the DOACs

From: DOACs – advances and limitations in real world

  Dabigatran [9, 38] Rivaroxaban [9, 40, 41] Apixaban [9, 37] Edoxaban [9, 39]
Target Factor IIa Factor Xa Factor Xa Factor Xa
Half-life (hour) 12-17 5-9 12 6-10
Time to peak effect (hour) 1-3 2-4 1-3 1-2
Renal clearance as unchanged drug (%) 80 33 27 50
Drug Interactions Pathways P-gp 3A4/P-gp 3A4/P-gp 3A4/P-gp
Dosing in non-valvular AF 150 mg BID 20 mg OD 5 mg BID 60 mg OD
Dosing in VTE treatment 150 mg BID after 5-10 days of parenteral anticoagulation 15 mg BID for 21 days followed by 20 mg OD 10 mg BID for 7 days followed by 5 mg BID 60 mg OD after 5 days of parenteral anticoagulation
  1. OD-once daily, BID-twice daily, P-gp – P-glycoprotein, 3A4 – cytochrome P450 3A4 isoenzyme